Valuation: Actavis Inc

Market Cap 6.37TCr 5.8TCr 5.34TCr 4.86TCr 9.12TCr 5,89500Cr 9.58TCr 65TCr 26TCr 3,22000Cr 24TCr 23TCr 10,10500Cr P/E 2018
-8.76x
P/E 2019 -11.9x
Enterprise Value 8.1TCr 7.37TCr 6.79TCr 6.18TCr 12TCr 7,49700Cr 12TCr 83TCr 33TCr 4,09500Cr 30TCr 30TCr 12,85200Cr EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
08/11 Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications CI
03/11 Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026 CI
21/10 Allergan Aesthetics presents its latest scientific advances Zonebourse
29/09 Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines CI
17/09 Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications CI
15/09 Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies CI
01/09 Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist CI
08/04 Allergan Aesthetics Opens New Ami Training Center in Austin CI
31/03 Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting CI
30/03 Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting CI
19/03 Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions CI
04/03 Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients CI
12/11 Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence CI
Manager TitleAgeSince
Director of Finance/CFO 56 01/12/2016
Director TitleAgeSince
Director/Board Member - 08/05/2020
Director/Board Member - 08/05/2020
Director/Board Member - 08/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-6.68%+27.12%+127.32% 1,20000Cr
+1.25%-5.35%+32.65%+78.98% 65TCr
+0.94%-2.99%+21.13%+106.30% 51TCr
-0.60%-1.95%+25.73%+67.00% 38TCr
+0.69%-9.50%+36.78%+30.83% 33TCr
+0.41%-4.70%+24.18%+50.18% 29TCr
+0.81%-4.08%-2.95%+31.59% 27TCr
-0.15%-6.45%+29.06%+65.76% 24TCr
-0.06%-0.98%+31.42%+122.83% 21TCr
Average +0.33%-4.76%+25.01%+75.64% 45TCr
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2018 2019
Net sales 1.58TCr 1.44TCr 1.32TCr 1.21TCr 2.26TCr 1,46200Cr 2.38TCr 16TCr 6.41TCr 80TCr 5.92TCr 5.8TCr 2,50600Cr 1.61TCr 1.47TCr 1.35TCr 1.23TCr 2.3TCr 1,49000Cr 2.42TCr 16TCr 6.53TCr 81TCr 6.04TCr 5.91TCr 2,55400Cr
Net income -509.64Cr -464.18Cr -427.72Cr -389.06Cr -729.9Cr -47TCr -767.11Cr -5.21TCr -2.07TCr -26TCr -1.91TCr -1.87TCr -81TCr -527.1Cr -480.08Cr -442.37Cr -402.39Cr -754.91Cr -49TCr -793.39Cr -5.38TCr -2.14TCr -27TCr -1.98TCr -1.94TCr -84TCr
Net Debt 2.19TCr 1.99TCr 1.84TCr 1.67TCr 3.14TCr 2,02700Cr 3.29TCr 22TCr 8.89TCr 1,10700Cr 8.21TCr 8.04TCr 3,47500Cr 1.73TCr 1.58TCr 1.45TCr 1.32TCr 2.48TCr 1,60200Cr 2.6TCr 18TCr 7.03TCr 88TCr 6.49TCr 6.36TCr 2,74700Cr
Logo Actavis Inc
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
-